{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["corr_drug"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"corr_drug","index":0,"n_rows":9,"n_cols":5,"rows_kept":9,"merged":[[0,0,0,4]],"flags":["formulas_cached_only"]}
["Table S5. Detailed  binding information of SAMD9 protein structure for hydrogen bonds formed from the screened drug candidates."]
["Drug","Maxium binding energy","No. of  hydrogne bonds formed","Binding site (amino acid residue)","Donor-acceptor distance (Å)"]
["Gemcitabine",-4.25,"None"]
["PARP inhibitor",-6.03,2,"Phe289, Asn171","2.8, 3.0"]
["Dasatinib",-4.81,2,"Glu286","2.7, 3.0"]
["Bleomycin",-2.82,2]
["THZ2",-5.65,4,"Ile284, Glu286, Asp167","2.8, 3.0, 3.1, 3.1"]
["Bortezomib","Not available","Not available"]
["PLK inhibitor",-3.8,"None"]